{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T04:13:40Z","timestamp":1685679220343},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study aimed to investigate the effect of androgen deprivation therapy (ADT) on the survival of intermediate-risk prostate cancer (IR-PCA) patients treated with dose-escalated external beam radiation therapy (DE-EBRT), and to determine the group that will benefit from ADT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analysed 620 IR-PCA patients treated with DE-EBRT at two institutions. Variables were adjusted using the stabilised inverse probability of treatment weighting method (sIPTW) between radiation therapy (RT) and RT plus ADT groups. Biochemical relapse-free survival (bRFS) rate and overall survival (OS) rate were compared using Kaplan\u2013Meier analysis and log-rank test. Cox proportional hazard analysis (CPH) was conducted to detect unfavorable risk factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This study included 405 patients; with 217 and 188 patients in the RT and RT plus ADT groups, respectively. The prescribed radiation dose was 78\u00a0Gy in 39 fractions. The median follow-up time was 82.0\u00a0months. After sIPTW-adjustment, 214.3 and 189.7 patients were assigned to the RT and RT plus ADT groups, respectively. The 7-year bRFS and OS were 89.3% and 94.6% in RT group and 92.3% and 91.0% in RT plus ADT group, respectively. Before and after sIPTW adjustment, no statistically significant differences were found in these endpoints between treatment groups. Multivariate CPH for bRFS revealed Gleason score (GS) 4\u00a0+\u00a03 as an unfavorable risk factor, and ADT improved biochemical control of them.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>ADT may not always be effective in all Japanese IR-PCA patients treated with DE-EBRT, but it can improve biochemical control in patients with GS 4\u00a0+\u00a03.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyad019","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T11:46:13Z","timestamp":1679485573000},"page":"514-521","source":"Crossref","is-referenced-by-count":0,"title":["Intensity-modulated radiation therapy for intermediate-risk prostate cancer: does ADT still have an impact in the dose-escalated external beam radiation therapy era?"],"prefix":"10.1093","volume":"53","author":[{"given":"Takashi","family":"Soyano","sequence":"first","affiliation":[{"name":"Japan Self-Defense Forces Central Hospital Department of Radiology, , 1-2-24, Ikejiri, Setagaya-ku, Tokyo 154-8532 , Japan"},{"name":"Cancer Institute Hospital, Japanese Foundation for Cancer Research Department of Radiation Oncology, , 3-8-31, Ariake, Koto-Ku, Tokyo 135-8550 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuyo","family":"Kozuka","sequence":"additional","affiliation":[{"name":"University of Tokyo Hospital Department of Radiology, , 7-3-1, Hongo, Bunkyo-Ku, Tokyo 113-8655 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Kashihara","sequence":"additional","affiliation":[{"name":"Tokyo Radiation Oncology Clinic , 3-5-7, Ariake, Koto-Ku, Tokyo 135-0063 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Murakami","sequence":"additional","affiliation":[{"name":"Hiroshima University Department of Radiation Oncology, Graduate School of Biomedical Health Sciences, , 1-3-2 Kagamiyama, Higashihiroshima, Hiroshima 734-8551 , Japan"},{"name":"Cancer Institute, Japanese Foundation for Cancer Research Department of Physics, , 3-8-31, Ariake, Koto-Ku, Tokyo 135-8550 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Yonese","sequence":"additional","affiliation":[{"name":"Cancer Institute Hospital, Japanese Foundation for Cancer Research Department of Urology, , 3-8-31, Ariake, Koto-Ku, Tokyo 135-8550 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Sasamura","sequence":"additional","affiliation":[{"name":"Tokyo Medical and Dental University Department of Radiation Therapeutics and Oncology, , 1-5-45, Yushima, Bunkyo-Ku, Tokyo 113-8519 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Shimoyachi","sequence":"additional","affiliation":[{"name":"Cancer Institute Hospital, Japanese Foundation for Cancer Research Department of Radiation Oncology, , 3-8-31, Ariake, Koto-Ku, Tokyo 135-8550 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tairo","family":"Kashihara","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital Department of Radiation Oncology, , 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Cancer Institute Hospital, Japanese Foundation for Cancer Research Department of Radiation Oncology, , 3-8-31, Ariake, Koto-Ku, Tokyo 135-8550 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Oguchi","sequence":"additional","affiliation":[{"name":"Cancer Institute Hospital, Japanese Foundation for Cancer Research Department of Radiation Oncology, , 3-8-31, Ariake, Koto-Ku, Tokyo 135-8550 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"2023060113503045200_ref1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, version 2.2019","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2023060113503045200_ref2","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.juro.2018.01.002","article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO Guideline. Part II: recommended approaches and details of specific care options","volume":"199","author":"Sanda","year":"2018","journal-title":"J Urol"},{"key":"2023060113503045200_ref3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"2023060113503045200_ref4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with intermediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"2023060113503045200_ref5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.299.3.289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial","volume":"299","author":"D\u2019Amico","year":"2008","journal-title":"JAMA"},{"key":"2023060113503045200_ref6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"2023060113503045200_ref7","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.ijrobp.2010.01.009","article-title":"Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06","volume":"79","author":"Valicenti","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023060113503045200_ref8","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2010.04.004","article-title":"Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer","volume":"80","author":"Krauss","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023060113503045200_ref9","doi-asserted-by":"crossref","first-page":"165.e1","DOI":"10.1016\/j.urolonc.2015.11.004","article-title":"Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base","volume":"34","author":"Amini","year":"2016","journal-title":"Urol Oncol"},{"key":"2023060113503045200_ref10","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","article-title":"Short androgen suppression and radiation dose escalation for intermediate-and high-risk localized prostate cancer: results of EORTC trial 22991","volume":"34","author":"Bolla","year":"2016","journal-title":"J Clin Oncol"},{"key":"2023060113503045200_ref11","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1200\/JCO.2016.34.15_suppl.5021","article-title":"Does short-term androgen depletion add to high dose radiotherapy (80 Gy) in localized intermediate risk prostate cancer? Final analysis of GETUG 14 randomized trial (EU-20503\/NCT00104741)","volume":"34","author":"Dubray","year":"2016","journal-title":"J Clin Oncol"},{"key":"2023060113503045200_ref12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2020.10.023","article-title":"Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial","volume":"143","author":"Nabid","year":"2021","journal-title":"Eur J Cancer"},{"key":"2023060113503045200_ref13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"key":"2023060113503045200_ref14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.juro.2018.08.044","article-title":"International multicenter validation of an intermediate risk subclassification of prostate cancer managed with radical treatment without hormone therapy","volume":"201","author":"Berlin","year":"2019","journal-title":"J Urol"},{"key":"2023060113503045200_ref15","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.juro.2008.06.017","article-title":"Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen-deprivation therapy in nonmetastatic prostate cancer","volume":"180","author":"Gulley","year":"2008","journal-title":"J Urol"},{"key":"2023060113503045200_ref16","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3349\/ymj.2014.55.3.570","article-title":"Unrecognized kinetics of serum testosterone: impact on short-term androgen deprivation therapy for prostate cancer","volume":"55","author":"Koo","year":"2014","journal-title":"Yonsei Med J"},{"key":"2023060113503045200_ref17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11604-017-0630-2","article-title":"Acute and late complications after hypofractionated intensity modulated radiotherapy in prostate cancer","volume":"35","author":"Kozuka","year":"2017","journal-title":"Jpn J Radiol"},{"key":"2023060113503045200_ref18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijrobp.2021.07.1714","article-title":"Dose-based radiomic analysis (dosiomics) for intensity modulated radiation therapy in patients with prostate cancer: correlation between planned dose distribution and biochemical failure","volume":"112","author":"Murakami","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023060113503045200_ref19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jjco\/hyab167","article-title":"Outcomes of intensity-modulated radiation therapy for intermediate- or high-risk prostate cancer: a single-institutional study","volume":"52","author":"Sasamura","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2023060113503045200_ref20","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023060113503045200_ref21","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/sim.2174","article-title":"Adjusted Kaplan\u2013Meier estimator and log-rank test with inverse probability of treatment weighting for survival data","volume":"24","author":"Xie","year":"2005","journal-title":"Stat Med"},{"key":"2023060113503045200_ref22","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2023060113503045200_ref23","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023060113503045200_ref24","first-page":"1","article-title":"EAU-ESUR-ESTRO-SIOG guidelines on prostate cancer\/ Guias Europeas","author":"Mottet","year":"2018","journal-title":"Eur Assoc Urol"},{"key":"2023060113503045200_ref25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.purol.2012.12.006","article-title":"Curieth\u00e9rapie exclusive du cancer de la prostate par implants permanents: indications et r\u00e9sultats. Revue du CC-AFU prostate brachytherapy: indications and outcomes","volume":"23","author":"Hennequin","year":"2013","journal-title":"Prog Urol"},{"key":"2023060113503045200_ref26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2023060113503045200_ref27","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1200\/JCO.21.00855","article-title":"Short androgen suppression and radiation dose escalation in prostate cancer: 12-year results of EORTC Trial 22991 in patients with localized intermediate-risk disease","volume":"39","author":"Bolla","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023060113503045200_ref28","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0090-4295(00)00753-6","article-title":"Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy","volume":"56","author":"Chan","year":"2000","journal-title":"Urology"},{"key":"2023060113503045200_ref29","first-page":"1511","article-title":"Prognostic significance of primary Gleason pattern in Japanese men with Gleason score 7 prostate cancer treated with radical prostatectomy","volume":"31","author":"Miyake","year":"2013","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"2023060113503045200_ref30","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A contemporary prostate cancer grading system: a validated alternative to the Gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"key":"2023060113503045200_ref31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/cancers10040116","article-title":"Proton beam therapy alone for intermediate- or high-risk prostate cancer: an institutional prospective cohort study","volume":"10","author":"Arimura","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2023060113503045200_ref32","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/cancers12061690","article-title":"Optimal androgen deprivation therapy combined with proton beam therapy for prostate cancer: results from a multi-institutional study of the Japanese Radiation Oncology Study Group","volume":"12","author":"Murakami","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2023060113503045200_ref33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1470-2045(20)30730-0","article-title":"Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis","volume":"22","author":"Gharzai","year":"2021","journal-title":"Lancet Oncol"},{"key":"2023060113503045200_ref34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.20.02438","article-title":"Prostate radiotherapy with adjuvant androgen deprivation therapy (ADT) improves metastasis-free survival compared to neoadjuvant ADT: an individual patient meta-analysis","volume":"39","author":"Spratt","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023060113503045200_ref35","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/6\/514\/50501097\/hyad019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/6\/514\/50501097\/hyad019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T13:53:35Z","timestamp":1685627615000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/53\/6\/514\/7082591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3,21]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad019","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,3,21]]}}}